Estimated: Skeletal Muscle Mass, Extra-Cellular Water (ICW), Total Body Water (ICW), Total Body Water (TBW), ECW/TBW, Body Fat, Percentage of Body Fat (PBF), Body Lean + Dry Lean, Metabolic Rates), Segmental Lean Mass, Segmental Fat Mass, % Segmental Body Fat, Energy Expenditure of Activity, Visceral Fat Area (VFA), Visceral Fat Level, Segmental Body Water, Percent Body Shape Graph, Weight Control, Fat Control, Muscle Control, Segmental ECW/TBW, Segmental ICW, TBW/LBM, Leg Lean Mass, Fitness Score, AC (Arm Circumference)

Actual: Weight, Body Mass Index (BMI) and Impedance Values, Height [which can require the entry of Height], Resistance Values [only for InBody S10], Reactance Values [only for InBody770, InBody S10], Phase Angle [only for InBody770, InBody S10]

Device Description

Impedance plethysmographic devices are used to estimate peripheral blood flow by measuring electrical impedance changes in a region of the body such as the arms and legs. Multi-frequency and segmental bioelectrical impedance analysis can estimate the distribution of body water (total body water; intra-cellular water), and can correlate with fluid compartmentalization. Assuming that body lean mass is hydrated in a constant and uniform manner; bioelectrical impedance analysis can be used to estimate body lean mass and fat mass.
These devices are impedance plethysmograph body composition analyzers. These devices determine body composition parameters based on bioelectrical impedance analysis (BIA). BIA relies on the differing behavior of biological tissues in response to an applied electrical current. Lean tissue is generally highly conductive because it contains large amounts of bound water and electrolytes, while fat tissue and bone are relatively poor conductors. By analyzing the response to electrical signals, BIA thereby permits differentiation of lean tissue, fat, and water and, in some instances, derivation of related body composition parameters. The total impedance resulting from BIA incorporates both resistance and capacitance components. Impedance plethysmographic devices are used to estimate peripheral blood flow by measuring electrical impedance changes in a region of the body such as the arms and legs. Multi-frequency and segmental bioelectrical impedance analysis can estimate the distribution of body water (total body water; intra-cellular water; extra-cellular water), and can correlate with fluid compartmentalization. Assuming that body lean mass is hydrated in a constant and uniform manner; bioelectrical impedance analysis can be used to estimate body lean mass and fat mass. Body composition analysis results may be of value to health care professionals in their management of the relative balance and levels of fat and lean tissue

AI/ML Overview

The Biospace Body Composition Analyzers (Models InBody770, InBody570, InBody S10, InBody230) were evaluated through a clinical study to demonstrate substantial equivalence to previously cleared predicate devices. The primary method of evaluation involved comparing the performance of the new devices against predicate devices across a range of body composition metrics.

1. Table of Acceptance Criteria and Reported Device Performance:

The document does not explicitly state "acceptance criteria" with numerical thresholds for performance. Instead, it relies on demonstrating comparable performance to predicate devices already cleared by the FDA, with "very nearly 1.00" correlation coefficients between the new devices and predicates as the key performance indicator.

Metric	Acceptance Criteria (Implied)	Reported Device Performance
Correlation Coefficient with Predicate Devices	Close to 1.00	Very nearly 1.00 for all four new units

2. Sample Size and Data Provenance:

Test Set Sample Size: Approximately 80 patients.
Data Provenance: The document does not explicitly state the country of origin. Given Biospace Corporation Limited is based in Seoul, Korea, it is highly probable the data originated from Korea. The study appears to be prospective as it states "We conducted clinical testing on each model."

3. Number and Qualifications of Experts for Ground Truth:

The document does not mention using experts to establish ground truth for the test set in the traditional sense (e.g., radiologists interpreting images). The study focuses on comparing the output of the new devices against predicate devices, implying that the predicate devices themselves serve as a form of "reference" or "ground truth" for comparative effectiveness in this context.

4. Adjudication Method:

Given that the ground truth appears to be based on the output of predicate devices, an adjudication method in the form of expert consensus is not applicable or mentioned in the document.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study:

An MRMC study was not conducted as this device does not involve human readers interpreting diagnostic images. The study compared device outputs directly. Therefore, there is no effect size of human improvement with or without AI assistance to report.

6. Standalone Performance Study:

A standalone performance study of the algorithm (if "algorithm" refers to the core BIA calculation logic) was implicitly done in the context of comparing the new devices against predicates. The reported "very nearly 1.00" correlation coefficients represent the standalone performance of the new devices relative to the established performance of the predicate devices. The study compares the device's measurement capabilities rather than an AI algorithm without human intervention.

7. Type of Ground Truth Used:

The primary "ground truth" for comparison was the measurements obtained from predicate devices. This is a form of comparative validation against established medical devices with a known performance profile.

8. Sample Size for the Training Set:

The document does not provide information regarding a separate training set or its sample size. As a medical device based on bioelectrical impedance analysis, its underlying principles and algorithms might be well-established, potentially requiring calibration and validation rather than extensive machine learning-style "training" on a specific dataset for output generation in the same way an AI image classification model would.

9. How Ground Truth for the Training Set Was Established:

As no explicit training set is mentioned in the provided text, the method for establishing its ground truth is not discussed.

Summary

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, stacked on top of each other to create a sense of depth and unity.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

September 23, 2014

Biospace Corporation Limited % Daniel Kamm Principal Engineer Kamm & Associates 8870 Ravello Ct Naples, FL 34114

Re: K141483

Trade/Device Name: Biospace Body Composition Analyzers, Model InBody770, InBody570, InBody S10, InBody230 Regulation Number: 21 CFR§ 870.2770 Regulation Name: Impedance plethysmograph Regulatory Class: II Product Code: MNW Dated: August 19, 2014 Received: August 22, 2014

Dear Daniel Kamm,

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies.

{1}------------------------------------------------

You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Image /page/1/Picture/6 description: The image shows the name "Benjamin R. Fisher -S" in a clear, sans-serif font. The text is horizontally aligned and appears to be part of a document or label. The letters are uniformly sized and spaced, contributing to the legibility of the name.

Benjamin R. Fisher, Ph.D. Director Division of Reproductive, Gastro-Renal, and Urological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) K141483

Device Name

Biospace Body Composition Analyzers, Model InBody770, InBody570, InBody S10, InBody230

Indications for Use (Describe) For use only in healthy subjects for Measurement of:

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.

FOR FDA USE ONLY

Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

510(k) Summary K141483 Biospace Corporation Limited Donghyun Building, 518-10 Dogok 2 - Dong Gangnam-Gu, Seoul, KOREA 135-854 Tel : +82-2-501-3939, Fax : +82-2-501-3978 Homepage : http://www.inbody.com DATE PREPARED: May 22, 2014 Contact: Kichul Cha, CEO

1. Identification of the Devices: Proprietary-Trade Names: Biospace Body Composition Analyzer, Model InBody770 Biospace Body Composition Analyzer, Model InBody570 Biospace Body Composition Analyzer, Model InBody S10 Biospace Body Composition Analyzer, Model InBody230 Classification Names: ANALYZER, BODY COMPOSITION Common/Usual Name: Body fat meter Requlation Description: Impedance plethysmograph. Classification Panel: Cardiovascular Product Code: MNW Regulation Number: 870. 2770 Classification: -
1. Equivalent legally marketed devices: (Predicate device Information) Biospace Body Composition Analyzer Model InBody 170, InBody J30 InBody S10, K110689 The Segmental Body Water indication was cleared in K123228, InBody 770, InBody570, InBodyS10, InBody H20.

3. Indications for Use:

For use only in healthy subjects for Measurement of:

Estimated: Skeletal Muscle Mass, Extra-Cellular Water (ECW), Intra-Cellular Water (ICW), Total Body Water (TBW), ECW/TBW, Body Fat, Percentage of Body Fat (PBF), Body Lean + Dry Lean, Metabolic Rates(Basal Metabolic Rates), Segmental Lean Mass, Segmental Fat Mass, % Segmental Body Fat, Energy Expenditure of Activity, Visceral Fat Area (VFA), Visceral Fat Level, Segmental Body Water, Percent Body Water, Body Shape Graph, Weight Control, Fat Control, Muscle Control, Segmental ECW/TBW, Segmental ICW, TBW/LBM, Leg Lean Mass, Fitness Score, AC (Arm Circumference)

Actual: Weight, Body Mass Index (BMI) and Impedance Values, Height [which can require the entry of Height], Resistance Values [only for InBody770, InBody S10], Reactance Values [only for InBody770, InBody S10], Phase Angle [only for InBody770, InBody S10]

1. Description: Impedance plethysmographic devices are used to estimate peripheral blood flow by measuring electrical impedance changes in a region of the body such as the arms and legs. Multi-frequency and segmental bioelectrical impedance analysis can estimate the distribution of body water (total body water; intra-cellular water), and can correlate with fluid compartmentalization. Assuming that body lean mass is hydrated in a constant and uniform manner; bioelectrical impedance analysis can be used to estimate body lean mass and fat mass.
  These devices are impedance plethysmograph body composition analyzers. These devices

{4}------------------------------------------------

determine body composition parameters based on bioelectrical impedance analysis (BIA). BIA relies on the differing behavior of biological tissues in response to an applied electrical current. Lean tissue is generally highly conductive because it contains large amounts of bound water and electrolytes, while fat tissue and bone are relatively poor conductors. By analyzing the response to electrical signals, BIA thereby permits differentiation of lean tissue, fat, and water and, in some instances, derivation of related body composition parameters. The total impedance resulting from BIA incorporates both resistance and capacitance components. Impedance plethysmographic devices are used to estimate peripheral blood flow by measuring electrical impedance changes in a region of the body such as the arms and legs. Multi-frequency and segmental bioelectrical impedance analysis can estimate the distribution of body water (total body water; intra-cellular water; extra-cellular water), and can correlate with fluid compartmentalization. Assuming that body lean mass is hydrated in a constant and uniform manner; bioelectrical impedance analysis can be used to estimate body lean mass and fat mass. Body composition analysis results may be of value to health care professionals in their management of the relative balance and levels of fat and lean tissue

1. Safety and Effectiveness, comparison to predicate device. The results of bench, safety, and software testing indicates that the new devices are as safe and effective as the predicate device.

Devices		InBody 170	InBody J30	InBody S10	InBody 770 (new)	InBody 570 (new)	InBody S10 (new)	InBody 230 (new)
510(k) number		K110689	K110689	K110689	New	New	New	New
Manufact-urer		Biospace	Biospace	Biospace	Biospace	Biospace	Biospace	Biospace
Measurement of Estimated	Extra-Cellular Water (ECW)	√	√	√	√	√	√	√
	Intra-Cellular Water(ICW)	√	√	√	√	√	√	√
	Total Body Water (TBW)	√	√	√	√	√	√	√
	Skeletal Muscle Mass	√	√	√	√	√	√	√
	Body Fat Mass	√	√	√	√	√	√	√
	Lean Body Mass	√	√	√	√	√	√	√
	Dry Lean Mass	√	√	√	√	√	√	√
	Basal Metabolic Rates	√	√	√	√	√	√	√
Devices		InBody170	InBodyJ30	InBodyS10	InBody770(new)	InBody570(new)	InBodyS10(new)	InBody230 (new)
	Segmental LeanMass	√	√	√	√	√	√	√
	ECW/TBW	√	√	√	√	√	√	√
	Segmental BodyFatmass %	√	√	√	√	√	√	√
	Segmental BodyFat	√	√	√	√	√	√	√
	Energyexpenditure ofactivity	√	√	√	√	√	√	√
	VisceralFat Area	√	√	√	√	√	√	√
	Segmental BodyWater			√	√	√	√
Measurement ofActual :	Weight	√	√		√	√		√
	Height		√
	BodyMassIndex(BMI)	√	√	√	√	√	√	√
	ImpedanceValues	20,100kHz	5, 50,250kHz	1, 5, 50,250, 500,1,000kHz	1, 5, 50,250, 500,1,000kHz	5, 50,500kHz	1, 5, 50,250, 500,1,000kHz	20,100kHz
	ReactanceValues			5,50,250kHz	5,50,250kHz		5,50,250kHz
	PhaseAngle			5,50,250kHz	5,50,250kHz		5,50,250kHz
	Measurementmethod	BioelectricalImpedance	BioelectricalImpedance	BioelectricalImpedance	BioelectricalImpedance	BioelectricalImpedance	BioelectricalImpedance	BioelectricalImpedance
	Electrodetype	4 electricpoles 8pointsTouchtypeelectrodemeasurement	4 electricpoles 8pointsTouchtypeelectrodemeasurement	4 electricpoles 8pointsTouchtypeelectrodemeasurement	4 electricpoles 8pointsTouchtypeelectrodemeasurement	4 electricpoles 8pointsTouchtypeelectrodemeasurement	4 electricpoles 8pointsTouchtypeelectrodemeasurement	4 electricpoles 8pointsTouchtypeelectrodemeasurement
Devices	InBody170	InBodyJ30	InBodyS10	InBody770(new)	InBody570(new)	InBodyS10(new)	InBody230 (new)
	Inputpower: AC100-120/200-240V,	Inputpower: AC100-120/200-240V,	Inputpower: AC100-120/200-240V,	Inputpower: AC100-120/200-240V,	Inputpower: AC100-120/200-240V,	100-240V~,50/60Hz	Inputpower: AC100-120/200-240V,
Power Source	50/60Hz,1.2AOutputpower:DC12V,3.4A	50/60Hz,1.2AOutputpower:DC12V,3.4A	50/60Hz,1.2AOutputpower:DC12V,3.4A	50/60Hz,1.2AOutputpower:DC12V,3.4A	50/60Hz,1.2AOutputpower:DC12V,3.4A	Noadapter	50/60Hz,1.2AOutputpower:DC12V.3.5A
Equipment weight	14.3kg	29kg	2kg	5.7kg	20 kg	45kg	26kg
Equipment size	396(W)×608(L)×955(H)mm	360(W)×640(L)×2235(H)mm	202(W)×322(L)×53(H):mm	393(W)×516(L)×732(H)mm	460(W)×677(L)×1020(H):mm	520(W)×870(L)×1200(H):mm	522 (W) ×843(L) ×1015(H):mm
Measurementtime	30seconds	30seconds	110seconds	Weightmeasurement 3~~5seconds,Impedancemeasurement 5~~7seconds.	45seconds	Less than1 minuteformedicalmode(Less than 2minutesforresearchpurposemode)	50seconds
Measurementage	From age3 ~ age 99	From age3 ~ age 99	From age3 ~ age 99	From age3 ~ age 99	From age3 ~ age 99	From age3 ~ age 99	From age3 ~ age 99
Measurement weight	10~250kg	10~250kg	10~250kg	5 ~ 250kg	10~250kg	10~250kg	10~250kg

6. Comparison table

{5}------------------------------------------------

{6}------------------------------------------------

Discussion of Non-Clinical Testing: Electromagnetic and Safety Testing was conducted 7. to IEC 60601-1 and IEC 60601-1-2. Software validation was conducted. Literature was compiled and reviewed.
1. Discussion of Clinical Testing: We conducted clinical testing on each model and compared the results to a predicate. Approximately 80 patients aged 6 to mid 60's, both males and females, were tested. The correlation coefficients for all four new units were very nearly 1.00 showing excellent correlation.
1. Conclusion: As compared to our predicate devices (our own brand) these new models have very similar technological characteristics and performed comparably to our predicates. The same scientific principles are used to produce the measurements. We therefore conclude that our new models are substantially equivalent to our predicate previously cleared. The new devices are therefore substantially equivalent to our predicates.

Regulation Number and Section

§ 870.2770 Impedance plethysmograph.

(a)
Identification. An impedance plethysmograph is a device used to estimate peripheral blood flow by measuring electrical impedance changes in a region of the body such as the arms and legs.(b)
Classification. Class II (special controls). The device, when it is a body composition analyzer which is not intended to diagnose or treat any medical condition, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 870.9.